Aesica Appoints Chris Gowland to the Newly Formed Position of COO
News Jul 29, 2013
Aesica has appointed Chris Gowland to the newly formed position of Chief Operating Officer.
As COO, Gowland has overall responsibility for all operating strategy. He leads international operational delivery, continuing to guarantee best in class on time in full (OTIF) services across the Aesica Group.
His remit encompasses the setting of operational standards and driving continuous improvement across the company’s manufacturing capabilities in API and Formulated Products.
Gowland is now responsible for operational performance and general management of all Aesica manufacturing sites including Queenborough and Cramlington in the UK, Monheim and Zwickau in Germany and Pianezza in Italy.
Under the new structure, Steve Barker, and Jarrett Palmer, Operations Directors for the API and Formulated Products business units respectively will report directly to the COO.
Gowland’s responsibilities also include the management of capital expenditure, procurement of materials and services, managing the supply chain and overseeing capacity expansion across the Group to ensure that Aesica meets full customer demand whilst delivering maximum service value.
Commenting on his role as COO, Chris Gowland remarked: “I am delighted to have the opportunity to lead a manufacturing structure in which I am responsible for driving highly efficient operational delivery and the highest standards of operational excellence across Aesica internationally.”
He continued: “Indeed the role is heavily directed at ensuring maximum value to our customers through the effective management of the Aesica supply chain. My intention is to delight our customers through fast, flexible and efficient product delivery to support their market needs and product development.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE